Patients
Recent intake assessments and their phenotype classifications.
| Patient | Recorded | Primary | Secondary | Confidence | |
|---|---|---|---|---|---|
| TEST-THOMAS-COURT | 2026-06-15 00:05:11.367762+00:00 | Mitochondrial dysfunction | Neuroinflammation | 54 · moderate | WorkspaceReview → |
| DEMO-009 | 2026-06-14 00:43:12.264704+00:00 | Babesia pattern | Bartonella pattern | 71 · moderate | WorkspaceReview → |
| DEMO-008 | 2026-06-14 00:43:02.670804+00:00 | Connective tissue | Gut-immune | 44 · low | WorkspaceReview → |
| DEMO-007 | 2026-06-14 00:42:56.241014+00:00 | Neuroinflammation | Mitochondrial dysfunction | 61 · moderate | WorkspaceReview → |
| DEMO-006 | 2026-06-14 00:42:47.178245+00:00 | Metabolic dysfunction | Dysautonomia | 29 · low | WorkspaceReview → |
| DEMO-005 | 2026-06-14 00:42:40.359003+00:00 | Immune dysregulation | Mold / CIRS pattern | 70 · moderate | WorkspaceReview → |
| DEMO-004 | 2026-06-14 00:42:34.449893+00:00 | Mitochondrial dysfunction | Dysautonomia | 81 · high | WorkspaceReview → |
| DEMO-003 | 2026-06-14 00:42:28.17124+00:00 | Mold / CIRS pattern | Mitochondrial dysfunction | 72 · moderate | WorkspaceReview → |
| DEMO-002 | 2026-06-14 00:42:18.435716+00:00 | Bartonella pattern | Neuroinflammation | 74 · moderate | WorkspaceReview → |
| DEMO-001 | 2026-06-14 00:32:22.823438+00:00 | Babesia pattern | Neuroinflammation | 52 · moderate | WorkspaceReview → |